Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) During Therapy With Spiolto Respimat [ELLACTO]
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Jan 2019
At a glance
- Drugs Olodaterol/tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms ELLACTO
- Sponsors Boehringer Ingelheim
- 04 Jan 2019 Planned End Date changed from 31 Dec 2018 to 22 Feb 2019.
- 04 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 19 Oct 2018 Planned primary completion date changed from 21 Sep 2018 to 9 Nov 2018.